Stefano Persiani
Stefano Persiani
Director Translational Sciences and Pharmacokinetics
Email confirmado em
TítuloCitado porAno
Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis
VB Kraus, B Burnett, J Coindreau, S Cottrell, D Eyre, M Gendreau, ...
Osteoarthritis and Cartilage 19 (5), 515-542, 2011
Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man
S Persiani, E Roda, LC Rovati, M Locatelli, G Giacovelli, A Roda
Osteoarthritis and cartilage 13 (12), 1041-1049, 2005
Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose
S Persiani, R Rotini, G Trisolino, LC Rovati, M Locatelli, D Paganini, ...
Osteoarthritis and Cartilage 15 (7), 764-772, 2007
Development and validation of a sensitive HPLC–ESI-MS/MS method for the direct determination of glucosamine in human plasma
A Roda, L Sabatini, A Barbieri, M Guardigli, M Locatelli, FS Violante, ...
Journal of Chromatography B 844 (1), 119-126, 2006
Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in …
AC Andreotti, E Pianezzola, S Persiani, MA Pacciarini, M Strolin Benedetti, ...
The Journal of Clinical Endocrinology & Metabolism 80 (3), 841-845, 1995
Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties
LC Rovati, F Girolami, S Persiani
Therapeutic advances in musculoskeletal disease 4 (3), 167-180, 2012
OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis
VB Kraus, FJ Blanco, M Englund, Y Henrotin, LS Lohmander, E Losina, ...
Osteoarthritis and cartilage 23 (5), 686-697, 2015
Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers
G Fornasini, N Monti, G Brogin, M Gallina, M Eandi, S Persiani, M Bani, ...
Chirality 9 (3), 297-302, 1997
Transcellular processing of disulfide‐and thioether‐linked peroxidase‐polylysine conjugates in cultured MDCK epithelial cells
J Wan, S Persiani, WC Shen
Journal of cellular physiology 145 (1), 9-15, 1990
Polylysine conjugates of Bowman–Birk protease inhibitor as targeted anti-carcinogenic agents
S Persiani, A Yeung, WC Shen, AR Kennedy
Carcinogenesis 12 (6), 1149-1152, 1991
Development and validation of a HPLC–ES-MS/MS method for the determination of glucosamine in human synovial fluid
E Pastorini, R Rotini, M Guardigli, S Vecchiotti, S Persiani, G Trisolino, ...
Journal of Pharmaceutical and Biomedical Analysis 50 (5), 1009-1014, 2009
Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay
S Persiani, F Broutin, P Cicioni, P Stefanini, MS Benedetti
European journal of pharmaceutical sciences 4 (6), 331-340, 1996
Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide
F Formelli, E Cavadini, R Luksch, A Garaventa, MG Villani, V Appierto, ...
Cancer chemotherapy and pharmacology 62 (4), 655-665, 2008
Glucosamine sulfate inhibits IL-1-stimulated gene expression at concentrations found in humans after oral intake.
T Piepoli, T Zanelli, O Letari, S Persiani, LC Rovati, G Caselli
Arthritis and Rheumatism 52 (9), S502-S503, 2005
A double‐blind, placebo‐controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor …
M Bani, A Colantoni, M Guillaume, F Macchi, G Moroni, S Persiani
British journal of clinical pharmacology 50 (4), 338-349, 2000
Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients.
S Persiani, R Rotini, G Trisolino, L Delliponti, LC Rovati, M Locatelli, ...
ARTHRITIS AND RHEUMATISM 52 (9), S508-S508, 2005
Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers
S Persiani, G Sassolas, G Piscitelli, CA Bizollon, I Poggesi, E Pianezzola, ...
Journal of pharmaceutical sciences 83 (10), 1421-1424, 1994
Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
PD Del, A Colzi, E Musatti, MB Strolin, S Persiani, R Fariello, U Bonuccelli
Clinical neuropharmacology 20 (5), 455-465, 1997
Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients
S Persiani, M D'Amato, F Makovec, SH Arshad, ST Holgate, LC Rovati
Biopharmaceutics & drug disposition 22 (2), 73-81, 2001
Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
S Persiani, M D'Amato, F Makovec, IA Tavares, PM Bishai, LC Rovati
International journal of clinical pharmacology and therapeutics 40 (5), 198-206, 2002
O sistema não pode efectuar a operação agora. Tente novamente mais tarde.
Artigos 1–20